Eurofins Scientific SE
ENXTPA-ERF
Company Overview
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Name
Eurofins Scientific SE
CEO
Gilles G. Martin
Website
www.eurofins.com
Sector
Life Sciences Tools and Services
Year Founded
1987
Company Statistics
Profile
Market Cap
—
EV
—
Shares Out
—
Revenue
—
Employees
—
Margins
Gross
—
EBITDA
—
Operating
—
Pre-Tax
—
Net
—
FCF
—
Returns (5Yr Avg)
ROA
—
ROTA
—
ROE
—
ROCE
—
ROIC
—
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
—
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
—
Net Debt
—
Debt/Equity
—
EBIT/Interest
—
Growth (CAGR)
Rev 3Yr
—
Rev 5Yr
—
Rev 10Yr
—
Dil EPS 3Yr
—
Dil EPS 5Yr
—
Dil EPS 10Yr
—
Rev Fwd 2Yr
—
EBITDA Fwd 2Yr
—
EPS Fwd 2Yr
—
EPS LT Growth Est
—
Dividends
Yield
—
Payout
—
DPS
—
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
—
Bulls Say
There are still sufficient acquisition targets left for Eurofins in its growth markets, allowing it to have continuous high growth while fortifying its competitive positioning through its hub-and-spoke network.
With its five-year capital investment program wrapping up, Eurofins is poised to start generating higher free cash flow and margin expansion.
Eurofins has shown signs of being able to raise pricing to combat wage inflation, which supports the view that the company has pricing power even in Europe.
Bears Say
Eurofins has achieved leading positions in key markets primarily through acquisitions. In the future, Eurofins may overpay on acquisitions to meet top-line targets.
Eurofins’ near-term successes in life sciences may prove transitory after the pandemic, as competitors will quickly crowd into the market to gain a piece of an attractive, profitable testing market.
Eurofins has heavily invested in its clinical diagnostics, which remain subscale to earn excess economic profits, and may need more capital. Meanwhile, reimbursement pressures could emerge before the desired scale benefits